908 Devices Earnings Call Signals Profitable Growth Path

908 Devices Inc. ((MASS)) has held its Q1 earnings call. Read on for the main highlights of the call.

908 Devices Inc.’s latest earnings call struck an optimistic tone despite some accounting noise and near-term integration drag. Management highlighted double-digit revenue growth, expanding margins, disciplined cash use and a sizable cash cushion, framing the NIRLAB acquisition as a strategic move to deepen recurring revenue and broaden markets. Investors were reminded that wider GAAP losses stem largely from noncash items rather than operational deterioration.

Revenue Growth

Total revenue reached $13.4 million in the first quarter of 2026, up 14% from $11.8 million a year earlier. Management framed this as evidence that demand for the company’s devices is strengthening, even as some ancillary revenue lines remain soft and program funding remains uncertain.

Handheld Product Momentum and Device Shipments

Handheld product and service revenue rose 16% year over year to $12.8 million, underscoring the core growth engine. The company shipped 167 devices, bringing its installed base to 3,903 units, and noted that VipIR shipments topped 25 in the quarter with ambitions to double or triple placements in 2025.

Gross Margin and Profitability Improvements

Gross profit climbed to $6.9 million, lifting reported gross margin to 51% from 47% a year earlier. On an adjusted basis, gross profit was $7.7 million with margins at 57%, roughly 290 basis points higher year over year, signaling improved mix and cost discipline.

Adjusted EBITDA Progress and Operating Discipline

The adjusted EBITDA loss narrowed sharply to $2.5 million from $4.6 million in the prior-year quarter, a 45% improvement. Cash use was held to just $1.2 million, suggesting the company is tightening spending while still investing in growth and integration initiatives.

Strengthened Balance Sheet

908 Devices closed the quarter with $111.7 million in cash, cash equivalents and marketable securities, and no debt outstanding. This balance sheet strength gives management ample flexibility to fund acquisitions like NIRLAB, support R&D and weather any timing hiccups in program or partnership revenue.

Strategic Acquisition of NIRLAB AG

The company announced the acquisition of NIRLAB AG for $15 million upfront with additional contingent equity of up to $8 million tied to milestones. NIRLAB brings more than 100 active customers, roughly 1 million analyses performed and a subscription-heavy model with over 99% annual retention, with expected contributions of about $2.5 million in 2026 revenue and more than $5 million in 2027.

Updated 2026 Guidance

Management raised full-year 2026 revenue guidance to a range of $67 million to $70 million, up $2.5 million from prior expectations and implying 19% to 25% growth versus 2025. Handheld revenue is projected at $62 million to $64 million, adjusted gross margins are seen in the mid to high 50% range and the adjusted EBITDA loss is expected to shrink to the mid-single-digit millions.

Commercial Traction in State & Local Channel

U.S. state and local customers accounted for about half of first-quarter revenue, underscoring the growing importance of this channel. The company reported that orders from these customers beat internal targets for a third straight quarter and highlighted a new $3 million order from a state corrections department booked in April.

Proof of M&A Integration Success (RedWave)

Management pointed to the RedWave acquisition as proof of its integration playbook, noting that RedWave surpassed its earn-out threshold by generating more than $37 million in cumulative revenue over the past two years. That compares with just $13.7 million in the year before the acquisition, suggesting prior M&A bets have translated into tangible growth.

Net Loss Widened

Despite operational improvements, net loss from continuing operations widened to $12.0 million from $9.8 million a year earlier. The primary driver was a $3.9 million noncash revaluation of contingent consideration, which does not affect cash but weighs on reported GAAP results.

Increase in Total Operating Expenses (Noncash Charge)

Total operating expenses climbed to $19.8 million from $16.6 million, again largely due to the $3.9 million noncash increase in the fair value of contingent consideration. Excluding that charge, other operating expenses actually fell by $0.7 million, reinforcing the narrative of tightening cost control.

Recurring Revenue Decline

Recurring revenue from consumables, accessories, software and service slipped 7% year over year to $4.0 million, representing 30% of total revenue. The decline was attributed mainly to an anticipated reduction in mass spectrometry service revenues, partially overshadowing the company’s broader push toward a recurring model.

Program Revenue Uncertainty

Program product and service revenue was effectively zero in the quarter versus $0.1 million a year earlier, as the company awaits fresh funding for the next phase of the AVCAD program. Management still expects $2 million to $3 million in AVCAD revenue, likely in the second half of 2026, but stressed that the timing remains contingent on program funding decisions.

NIRLAB Near-Term Profitability Headwind and Execution Risk

While NIRLAB is expected to be strategically accretive, management warned it will create roughly a $1 million adjusted EBITDA headwind in 2026. The business is still early in U.S. adoption and primarily international today, leaving execution risk around U.S. penetration and global scale-up in the near term.

Service Revenue Pressures on MX908

The MX908 platform saw higher device placements and contributed to the expanding installed base, but service revenue declined by $0.7 million. This pressure on service income contributed to the broader recurring revenue decline, tempering some of the otherwise strong hardware momentum.

OEM & Funded Partnership Softness

Revenue from OEM and funded partnerships came in at $0.6 million, slightly below the $0.7 million recorded a year earlier. The limited contribution from these channels underscores that near-term growth is being driven primarily by handheld devices and state and local demand rather than external partnerships.

Forward-Looking Guidance and Outlook

Looking ahead, 908 Devices expects total 2026 revenue between $67 million and $70 million, with handheld revenue of $62 million to $64 million and roughly $3 million from OEM and funded partnerships alongside $2 million to $3 million from the AVCAD program later in the year. Management anticipates adjusted gross margins in the mid to high 50% range and aims to reduce adjusted EBITDA losses to the mid-single-digit millions, while integrating NIRLAB, which is projected to add about $2.5 million in 2026 revenue and turn adjusted-EBITDA-positive by 2027.

The earnings call painted a picture of a company leaning into growth while keeping a firm grip on costs and cash. Strong handheld momentum, an expanding installed base and a strategic push into recurring revenue via NIRLAB and prior deals like RedWave are offsetting short-term noise in services and program funding. For investors, the story is one of improving operational leverage, a fortified balance sheet and a clearer path toward profitability, albeit with some integration and execution risks still in play.